---
title: FDA Greenlights Age-Reversing Eye Drops Using Yamanaka Factors
slug: "epigenetic-reprogramming-eye-disease-trial"
description: Life Biosciences' ER-100 uses Yamanaka factors to treat glaucoma and
  vision loss
date: '2026-02-17'
category: Clinical Trial
featured: false
author: Longevity Leak Research Team
study_url: https://www.fightaging.org/archives/2026/02/the-first-clinical-trial-of-partial-reprogramming-will-start-soon/
published: true
---
# FDA Greenlights Age-Reversing Eye Drops Using Yamanaka Factors

## What Is Actually Happening

This is an early clinical transition, not a proven reversal outcome in humans. The program uses partial epigenetic reprogramming logic (based on selected Yamanaka factors) and is targeting serious eye disease where treatment need is high.

Preclinical work in retinal models and non-human primates is the scientific basis for moving into human testing. The objective now is to establish feasibility and safety in carefully selected participants.

## Why the Eye Is a Logical First Target

Ophthalmology gives researchers high-quality imaging endpoints and relatively contained local delivery, which can reduce systemic exposure risk. That makes the eye one of the most practical settings for first-in-human reprogramming approaches.

For readers tracking longevity translation, this is an example of "high-upside, high-uncertainty" innovation. It belongs on a watchlist, not in a self-experiment protocol.

## Practical Interpretation

Today, the practical value is strategic, not clinical: it shows where the frontier is moving.

If your near-term goal is preserving function, evidence is still stronger for proven risk-control domains such as blood pressure, glucose, and sleep quality, plus condition-specific care paths like [Cognitive Decline Risk](/conditions/cognitive-decline-risk) and [Endothelial Function Decline](/conditions/endothelial-function-decline).

## Evidence Limits and What We Still Need

There is no mature human efficacy dataset yet. Early-stage trials are usually underpowered for hard outcomes, and long-term safety monitoring is critical for any reprogramming strategy. Dose control, durability, off-target risk, and patient-selection boundaries remain uncertain.

## Sources

1. [Program and trial context](https://www.fightaging.org/archives/2026/02/the-first-clinical-trial-of-partial-reprogramming-will-start-soon/)
2. [Partial reprogramming preclinical context (Nature)](https://www.nature.com/articles/s41586-020-2975-4)
